Journal of Hepatology
Volume 53, Issue 2 , Pages 348-356 , August 2010

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review

  • George V. Papatheodoridis

      Affiliations

    • 2nd Department of Internal Medicine, Athens University Medical School, Athens, Greece
    • Corresponding Author InformationCorresponding author. Address: 2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, 114 Vas. Sophias Ave., 115 27 Athens, Greece. Tel.: +30 210 7774742; fax: +30 210 7706871.
    • ,
  • Pietro Lampertico

      Affiliations

    • 1st Division of Gastroenterology, Fondazione Policlinico IRCCS Ospedale Maggiore, Mangiagalli e Regina Elena, Università degli Studi di Milano Milan, Italy
    • ,
  • Spilios Manolakopoulos

      Affiliations

    • 2nd Department of Internal Medicine, Athens University Medical School, Athens, Greece
    • ,
  • Anna Lok

      Affiliations

    • Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA

References 

  1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576
  2. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet. 1999;353:1253–1257
  3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750
  4. Okuda K. Hepatocellular carcinoma. J Hepatol. 2000;32:225–237
  5. Maringhini A, Cottone M, Sciarrino E, Marceno MP, La Seta F, Fusco G, et al. Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Dig Dis Sci. 1988;33:47–51
  6. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101:1348–1355
  7. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol. 2000;61:362–366
  8. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73
  9. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–539
  10. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis. 2008;8:167–178
  11. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–242
  12. Craxi A, Di Bona D, Camma C. Interferon-a for HBeAg-positive chronic hepatitis B. J Hepatol. 2003;39:S99–S105
  13. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon – a treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001;34:306–313
  14. Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology. 2003;37:756–763
  15. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46:45–52
  16. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology. 2001;34:139–145
  17. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008;28:1067–1077
  18. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714–1722
  19. Andreone P, Gramenzi A, Cursaro C, Biselli M, Camma C, Trevisani F, et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat. 2004;11:439–442
  20. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40:883–891
  21. Gaia S, Marzano A, Smedile A, Barbon V, Abate ML, Olivero A, et al. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment Pharmacol Ther. 2004;20:281–287
  22. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531
  23. Gish RG, Trinh H, Leung N, Chan FK, Fried MW, Wright TL, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol. 2005;43:60–66
  24. Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ. Response to long-term lamivudine treatment (up to 5years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat. 2005;12:398–404
  25. Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, et al. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study. J Med Virol. 2005;75:491–498
  26. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology. 2005;42:121–129
  27. Di Marco V, Di Stefano R, Ferraro D, Almasio PL, Bonura C, Giglio PM, et al. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther. 2005;10:431–439
  28. Manolakopoulos S, Bethanis S, Elefsiniotis J, Karatapanis S, Triantos C, Sourvinos G, et al. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome. Aliment Pharmacol Ther. 2006;23:787–795
  29. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5years. Gastroenterology. 2006;131:1743–1751
  30. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007;45:307–313
  31. Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol. 2007;47:366–372
  32. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther. 2007;12:1295–1303
  33. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007;133:1445–1451
  34. Wong VW, Wong GL, Tsang SW, Hui AY, Chim AM, Yiu KK, et al. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Antivir Ther. 2008;13:571–579
  35. Kilic ZM, Kuran S, Akdogan M, Cicek B, Oguz D, Odemis B, et al. The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis. Adv Ther. 2008;25:190–200
  36. Nishida T, Kobashi H, Fujioka S, Fujio K, Takaguchi K, Ikeda H, et al. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. J Gastroenterol Hepatol. 2008;23:794–803
  37. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil. Intervirology. 2008;51:385–393
  38. Idilman R, Kaymakoglu S, Oguz OF, Ahishali E, Bektas M, Cinar K, et al. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. J Viral Hepat. 2009;16:279–285
  39. Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med. 1981;305:1067–1073
  40. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 2001;120:1763–1773
  41. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172∗ mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology. 2008;48:88–98
  42. Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther. 2008;13:875–879

PII: S0168-8278(10)00331-4

doi: 10.1016/j.jhep.2010.02.035

Journal of Hepatology
Volume 53, Issue 2 , Pages 348-356 , August 2010

Article Tools

* Image Usage & Resolution